Literature DB >> 16794810

Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations.

Heike Meiselbach1, Anselm H C Horn, Thomas Harrer, Heinrich Sticht.   

Abstract

Drug resistance is a very important factor contributing to the failure of current HIV therapies. The ability to understand the resistance mechanism of HIV-protease mutants may be useful in developing more effective and longer lasting treatment regimens. In this paper, we report the first computational study of the clinically relevant E35D mutation of HIV-1 protease in its unbound conformation and complexed with the clinical inhibitor amprenavir and a sample substrate (Thr-Ile-Met-Met-Gln-Arg). Our data, collected from 10 ns molecular-dynamics simulations, show that the E35D mutation results in an increased flexibility of the flaps, thereby affecting the conformational equilibrium between the closed and semi-open conformations of the free protease. The E35D mutation also causes a significant reduction of the calculated binding free energies both for substrate and amprenavir, thus giving a plausible explanation for its ability to increase the level of resistance. One possible explanation for the emergence of this mutation, despite its unfavorable effect on substrate affinity, might be the role of E35D as an escape mutation, which favors escape from the immune system in addition to conferring drug resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794810     DOI: 10.1007/s00894-006-0121-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  24 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Simultaneous prediction of binding capacity for multiple molecules of the HLA B44 supertype.

Authors:  John Sidney; Scott Southwood; Valerie Pasquetto; Alessandro Sette
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

3.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

4.  A modified version of the Cornell et al. force field with improved sugar pucker phases and helical repeat.

Authors:  T E Cheatham; P Cieplak; P A Kollman
Journal:  J Biomol Struct Dyn       Date:  1999-02

5.  Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance.

Authors:  W R Scott; C A Schiffer
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

6.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

Authors:  S W Kaldor; V J Kalish; J F Davies; B V Shetty; J E Fritz; K Appelt; J A Burgess; K M Campanale; N Y Chirgadze; D K Clawson; B A Dressman; S D Hatch; D A Khalil; M B Kosa; P P Lubbehusen; M A Muesing; A K Patick; S H Reich; K S Su; J H Tatlock
Journal:  J Med Chem       Date:  1997-11-21       Impact factor: 7.446

Review 7.  Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

Authors:  Cédric Arvieux; Olivier Tribut
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Authors:  Anne-Geneviève Marcelin; Claire Lamotte; Constance Delaugerre; Nadine Ktorza; Hocine Ait Mohand; Raquel Cacace; Manuela Bonmarchand; Marc Wirden; Anne Simon; Philippe Bossi; François Bricaire; Dominique Costagliola; Christine Katlama; Gilles Peytavin; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution.

Authors:  M Miller; J Schneider; B K Sathyanarayana; M V Toth; G R Marshall; L Clawson; L Selk; S B Kent; A Wlodawer
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

10.  Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA.

Authors:  Alasdair Leslie; Daniel Kavanagh; Isobella Honeyborne; Katja Pfafferott; Charles Edwards; Tilly Pillay; Louise Hilton; Christina Thobakgale; Danni Ramduth; Rika Draenert; Sylvie Le Gall; Graz Luzzi; Anne Edwards; Christian Brander; Andrew K Sewell; Sarah Moore; James Mullins; Corey Moore; Simon Mallal; Nina Bhardwaj; Karina Yusim; Rodney Phillips; Paul Klenerman; Bette Korber; Photini Kiepiela; Bruce Walker; Philip Goulder
Journal:  J Exp Med       Date:  2005-03-21       Impact factor: 14.307

View more
  13 in total

1.  A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.

Authors:  Pia Rücker; Anselm H C Horn; Heike Meiselbach; Heinrich Sticht
Journal:  J Mol Model       Date:  2011-01-29       Impact factor: 1.810

2.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

3.  Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.

Authors:  Sandra M Mueller; Birgit Schaetz; Kathrin Eismann; Silke Bergmann; Michael Bauerle; Matthias Schmitt-Haendle; Hauke Walter; Barbara Schmidt; Klaus Korn; Heinrich Sticht; Bernd Spriewald; Ellen G Harrer; Thomas Harrer
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

4.  Molecular dynamics studies on HIV-1 protease: a comparison of the flap motions between wild type protease and the M46I/G51D double mutant.

Authors:  Antonino Lauria; Mario Ippolito; Anna Maria Almerico
Journal:  J Mol Model       Date:  2007-09-06       Impact factor: 1.810

5.  The role of select subtype polymorphisms on HIV-1 protease conformational sampling and dynamics.

Authors:  Xi Huang; Manuel D Britto; Jamie L Kear-Scott; Christopher D Boone; James R Rocca; Carlos Simmerling; Robert Mckenna; Michael Bieri; Paul R Gooley; Ben M Dunn; Gail E Fanucci
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

6.  Inhibitor-induced conformational shifts and ligand-exchange dynamics for HIV-1 protease measured by pulsed EPR and NMR spectroscopy.

Authors:  Xi Huang; Ian Mitchelle S de Vera; Angelo M Veloro; Mandy E Blackburn; Jamie L Kear; Jeffery D Carter; James R Rocca; Carlos Simmerling; Ben M Dunn; Gail E Fanucci
Journal:  J Phys Chem B       Date:  2012-11-30       Impact factor: 2.991

7.  Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease.

Authors:  Pia Dirauf; Heike Meiselbach; Heinrich Sticht
Journal:  J Mol Model       Date:  2010-02-27       Impact factor: 1.810

8.  Drug resistance mutations in protease gene of HIV-1 subtype C infected patient population.

Authors:  Mohammad Misbah; Poonam Gupta; Gaurav Roy; Suresh Kumar; Mohammad Husain
Journal:  Virusdisease       Date:  2021-07-13

9.  Mutations in herpes simplex virus gD protein affect receptor binding by different molecular mechanisms.

Authors:  Joachim D Stump; Heinrich Sticht
Journal:  J Mol Model       Date:  2014-03-20       Impact factor: 1.810

10.  Elasticity-Associated Functionality and Inhibition of the HIV Protease.

Authors:  Dean Sherry; Roland Worth; Yasien Sayed
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.